{
    "nctId": "NCT00470704",
    "briefTitle": "Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer",
    "officialTitle": "A Phase 2 Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 87,
    "primaryOutcomeMeasure": "Objective Response Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed invasive breast cancer, with stage IV disease\n* HER2-positive breast cancer, defined as 3+ staining by IHC or gene amplification by FISH\n* Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension\n* Willingness to undergo a research biopsy of recurrent or metastatic disease\n* Prior chemotherapy treatment must be discontinued for at least 2 weeks prior to study entry.\n* Completed radiation therapy at least 7 days prior to beginning protocol treatment\n* Cohort 1: No prior chemotherapy for advanced breast cancer; no prior trastuzumab in the advanced breast cancer setting; nor prior treatment with lapatinib or other HER2-directed therapy other than trastuzumab\n* Cohort 2: Up to two prior chemotherapy regimens for the treatment of advanced breast cancer; no prior treatment with lapatinib or other HER2-directed therapy except for trastuzumab\n* 18 years of age or older\n* Life expectancy of greater than 12 weeks\n* ECOG Performance Status 0-2\n* Normal organ and marrow function as outlined in protocol\n* Cardiac ejection fraction, as assessed by either MUGA scan or echocardiogram greater than or equal to 50%\n* Able to take oral medications\n\nExclusion Criteria:\n\n* Patients may not be receiving any other investigational agents or concurrent chemotherapy or hormonal therapy for treatment of metastatic disease\n* Active brain metastases\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib or other agents used in this study\n* Clinically significant malabsorption syndrome\n* Uncontrolled intercurrent illness\n* Pregnant or breastfeeding women\n* Concurrent use of the medications listed in the protocol because of possible interaction with lapatinib",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}